Podcast Index
Browse podcasts by category, open recent episodes, and download audio to listen offline.
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist
Unwritten with Steph
Stephanie Shanks
Nonfiction Kidlit Craft Conversations
Kirsten W. Larson
And It's Live! A Retro Football Podcast
Playback Media Ltd
A hora milagrosa
Maria Janete Santos Gil
Comprendre le monde : les podcasts de décryptage
Acast France
Lurie Breaks It Down
Women's Empowerment Network, SiriusXM
Forgotten Felonies
Forgotten Felonies Podcast
Pistons Daily | Detroit Pistons Daily Podcast
Fan Arch
Blackhawks Daily | Chicago Blackhawks Daily Podcast
Fan Arch
In the Groove with Todd and Jackie
Todd Alan Cudaback & Jackie Bailey
Utah Mammoth Daily | Utah Mammoth Daily Podcast
Fan Arch
Crown Global Media
Crown Global Media
Women of Jewelry
Linda Kozloff-Turner and Nathalia Guarascio
The Daily Heretic
Andrew Gold
Sleepy Wisdom | Grandpa Huxley
Grandpa Huxley
Halo Territory: A Los Angeles Angels Podcast
Foul Territory Network
Liverpool Latest | Daily Liverpool FC Podcast
Fan Arch
St. Louis Cardinals Daily | St. Louis Cardinals Daily Podcast
Fan Arch
Sharks Latest | San Jose Sharks Daily Podcast
Fan Arch
Hollywood Unfiltered
Sloan
The Profitable Horse Business Podcast
Audrey McLaughlin
Talking Billions with Bogumil Baranowski
Bogumil Baranowski
Cuentos y Leyendas de Honduras
Cuentos y Leyendas de Honduras
El Podcast de Soycomocomo con Núria Coll
Soycomocomo
Zasypiaki
Adam Szustak OP
Greaseman Bits from the 70's 80's and 90's
Carlos
The Kevin Karius Show
Sports 1440
Radio Foot Internationale
RFI
Becoming a Bowhunter
Matty | Becoming A Bowhunter
The Ricochet Superfeed
Ricochet
The Sons Of Liberty
The Sons of Liberty
レアジョブ英会話 Daily News Article Podcast
RareJob
El Pulso del Fútbol
Caracol Podcast
Milk Road Macro
Milk Road
Mahlakung
Thobela FM
120 Minutos
Radio Monumental
All
David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist
The cell and gene therapy industry faces massive hurdles—cost, scalability, and the need for highly skilled operators have historically limited the reach of these transformative treatments. advanced therapy medicinal pro...
What if the simple act of opening an incubator could undermine the consistency of your cell therapy manufacturing process? Unlike traditional biologics, the moment cells leave their incubator, subtle shifts in temperatur...
Digital transformation in biotech is no longer just about adopting new tools, it's about building a foundation where automation, data standardization, and AI integration actually lead to real value and long-term success....
Despite cutting-edge equipment and brilliant minds, biotech labs often find half their data trapped in difficult-to-access spreadsheets or isolated in silos, making true digital transformation a major, industry-wide hurd...
Host David Brühlmann returns for a focused solo episode to provide an honest, data-driven perspective on the evolving landscape of host selection for biologics manufacturing. Building on part one, David reviews five alte...
In this solo episode, David Brühlmann explores the evolving landscape of biologic manufacturing platforms beyond CHO (Chinese hamster ovary) cells. Drawing from previous interviews with platform pioneers and rigorous dat...
Funding novel therapeutics isn’t just “harder than ever”—the rules have changed entirely. The wild rush of capital into early-stage biotech during 2020–2021 gave way to a drought, making investor priorities sharper and s...
Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.Michael Rome, who leads therapeutics investing at Foresite Capital, brings a rare dual lens as both sci...
What happens between scientific discovery and clinical trials? For too many drug candidates, the answer is “failure”—not because the idea lacked merit, but because the critical handoff between discovery and IND-enabling ...
The gap between a “drug” and a true “product” is where many therapies fail.Milan Tomic, biotech veteran, GMP manufacturing expert, and founder of Albrem, has spent 30 years turning promising science into scalable, execut...
The "data lake" that was supposed to unify bioprocessing intelligence has, in most companies, become something else entirely: a data swamp, where information goes in and insight rarely comes back out. For anyone trying t...
When AI can draft a literature review in minutes, the question bioprocess educators can no longer avoid is this: what does a student actually need to learn?Steffen Kreye has a clear answer. As Professor of Industrial Bio...
Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?In Part 1, Yuta Lee, Founder and CEO of Accelerated Bio, walked through the biol...
What if the key to scalable, off-the-shelf cell therapy was hiding in tissue that surgeons discard every day?Yuta Lee, Founder and CEO of Accelerated Bio, has spent two decades building a cell therapy platform on exactly...
Are you still using one-factor-at-a-time experiments for biosimilar development, losing months, missing interactions, and risking costly dead-ends?In this episode, David Brühlmann, host of the Smart Biotech Scientist Pod...
Are you stuck screening endless compounds in biosimilar development and still not hitting your quality targets? Efficient compound screening is one of the toughest bottlenecks in biopharma, with outdated methods slowing ...
When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from process development into the broader consequences of that reality: the manufac...
The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the patient. Chantale Bernatchez has spent 20 years learning that lesson the ...
Getting an NDA signed shouldn't take weeks. If your CRO needs more than 48 hours to start the paperwork, your project timeline is already moving in the wrong direction.Ron Najafi knows what rigorous analytical work actua...
When drug safety fails, patients and entire markets pay the price. Understanding your CMC isn't just compliance — it's the line between therapeutic promise and product recall.Ron Najafi has lived that reality firsthand. ...
Fill in the form below. Make sure to select both Country and Genres.
Send us a message below. We will get back to you within 24 hours.